LipoNova AG: Local Supervisory Agency Approves Production license of LipoNova’s Early-Stage Kidney Cancer Vaccine Reniale®   ***   LipoNova AG reaches key milestones in the Reniale development process during 2007. Costs below budget.   ***   LipoNova signs memorandum of understanding for the marketing of Reniale®   ***   
Our Business

Company Profile

  • October 1998, company founded
  • ~ 30 employees
  • Development of innovative compounds against cancer
  • Field of Expertise: autologous tumour vaccines for adjuvant treatment of renal cell carcinoma
  • International advisory boards and expert network established
  • Product candidates in clinical and very early preclinical development

Achievements with the lead product Reniale®

  • Successful conclusion of a Phase-III Clinical Study in 2003 using Reniale® as an adjuvant therapy for renal cell carcinoma
  • Passing peer review and publication in Lancet 2004, long term data of Phase III Clinical Study presented in poster presentation, Bio Boston, 2007
  • Statistically significant disease-free survival and overall survival demonstrated with a good quality of life in treated patients
  • Orphan drug status for Reniale® in 2002 (Europe)
  • Start of an international Phase-III Clinical Study using Reniale® as an adjuvant therapy for renal cell carcinoma in 2008
  • Successful FDA Pre-IND meeting confirms pathway to approval